PHACYLOB: Pharmacokinetics of Methylphenidate in Adults With and Without Obesity

Phase 4, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by CHRU Tours. Primary endpoint: Area under the curve (AUC) of methylphenidate and alpha-phenyl-2-piperidine acetic acid plasma concentrations up to 8 hours after administration. Planned start Apr 2025; status: authorised.